
Nov 26 (Reuters) - Collplant Biotechnologies Ltd CPTG.F:
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
COLLPLANT BIOTECHNOLOGIES 9M OPERATING EXPENSES USD 10 MILLION
COLLPLANT BIOTECHNOLOGIES 9M ADJUSTED NET INCOME USD -7 MILLION
COLLPLANT BIOTECHNOLOGIES 9M ADJUSTED EPS USD -0.58
COLLPLANT BIOTECHNOLOGIES 9M REVENUE USD 2.3 MILLION
COLLPLANT BIOTECHNOLOGIES 9M NET INCOME USD -8.3 MILLION
COLLPLANT BIOTECHNOLOGIES 9M EPS USD -0.69
COLLPLANT BIOTECHNOLOGIES LTD - RECENTLY UPDATED ITS EXPENSE FORECAST AND HAS INITIATED A COST CUTTING AND WORKFORCE REDUCTION PLAN
COLLPLANT BIOTECHNOLOGIES: UPDATED ALLOCATION OF RESOURCES TO RESULT IN REDUCTION IN WORKFORCE BY ABOUT 25%
COLLPLANT BIOTECHNOLOGIES LTD - ROGER POMERANTZ STEPS DOWN AS CHAIRMAN; YEHIEL TAL NOMINATED AS INTERIM CHAIRMAN
COLLPLANT BIOTECHNOLOGIES LTD - ROGER POMERANTZ STEPS DOWN AS CHAIRMAN; YEHIEL TAL NOMINATED AS INTERIM CHAIRMAN